Carveol

Carveol

SCHEMBL564464

C=C(C)[C@@H]1CC=C(C)[C@@H](O)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 1.00
TP53 P04637 1/20 1.00
ALOX15 P16050 3/20 0.56
LMNA P02545 4/20 0.48
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TRPA1 O75762 1/20 0.43
CYP1B1 Q16678 1/20 0.41
KDM4E B2RXH2 1/20 0.32
MAPT P10636 2/20 0.31
MAPK1 P28482 2/20 0.31
ALOX12 P18054 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carveol SCHEMBL26201044 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL15011317 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL180292 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL18339543 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL14763904 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL20201316 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL15011580 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL56868 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL20586300 1.00 TSHR (1.00) TSHRTP53ALOX15LMNAALDH1A1
Carveol SCHEMBL23706303 0.88 TSHR (0.78) TSHRTP53ALOX15LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598425-A1 DETECTION OF LIVER DISEASE Owlstone Medical Limited (GB) 2025-08-13 EP claimed
CN-119709448-A Construction and application of biosynthesis of (-) -carvone strain by utilizing saccharomyces cerevisiae and peroxisome localization 中国科学院天津工业生物技术研究所 2025-03-28 CN claimed
CN-118583998-A Method for rapidly identifying star anise and shikimia based on ultra-rapid gas-phase electronic nose and BP neural network 江苏省中医院 2024-09-03 CN claimed
CN-114847309-B Mixed extract of fructus Piperis Longi, flos Chrysanthemi Indici extract and application of the same in strawberry disease control 湖北工程学院 2024-07-19 CN claimed
WO-2024074826-A1 DETECTION OF LIVER DISEASE OWLSTONE MEDICAL LIMITED (GB) 2024-04-11 WO claimed
CN-116120989-B Spice with sweet fruit flavor and compound flavor and preparation method and application thereof 云南中烟工业有限责任公司 2024-01-19 CN claimed
WO-2023187598-A1 COMPOSITIONS AND METHODS BIBLICAL LANDS LTD (IL) 2023-10-05 WO claimed
EP-4243619-A1 CITRUS OIL EXTRACT Firmenich SA (CH) 2023-09-20 EP claimed
EP-4229639-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS Global Biopharma, Inc. (CA) 2023-08-23 EP claimed
CN-116261399-A Citrus oil extract 弗门尼舍有限公司 2023-06-13 CN claimed
US-20060127517-A1 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response META PROTEOMICS, LLC 2006-06-15 US claimed
CN-1742953-A Plant cell regulator YUKUN LIAO (HK) 2006-03-08 CN claimed
EP-1558271-A4 COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE METAPROTEOMICS LLC (US) 2006-01-11 EP claimed
US-20050260725-A1 Process for the preparation of trans-carveol EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2005-11-24 US claimed
EP-1558271-A2 COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE Metaproteomics, LLC (US) 2005-08-03 EP claimed
US-20040151792-A1 Compositions that treat or inhibit pathological conditions associated with inflammatory response FORTRESS CREDIT CORP. (AS COLLATERAL AGENT) 2004-08-05 US claimed
WO-2004037180-A2 COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE METAPROTEOMICS, LLC (US) 2004-05-06 WO claimed
US-20040086580-A1 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response META PROTEOMICS, LLC 2004-05-06 US claimed
EP-1205556-A1 Process for the preparation of trans-carveol AVENTIS ANIMAL NUTRITION S.A. (FR) 2002-05-15 EP claimed
US-3956404-A PINENE, CUPROUS CHLORIDE OR BROMIDE, BENZOYL PEROXIDE, MIXING LEVER BROTHERS COMPANY (US) 1976-05-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040086580-A1 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response HPGDS, TPSB2, TPSG1 TSHR 3439/4885TP53 1700/4885ALOX15 219/4885
US-20040151792-A1 Compositions that treat or inhibit pathological conditions associated with inflammatory response HPGDS, TPSB2, HMGB2 TSHR 3592/4885TP53 1863/4885ALOX15 147/4885
US-20060127517-A1 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response HPGDS, TPSB2, TPSG1 TSHR 3439/4885TP53 1700/4885ALOX15 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.